Accueil>>Signaling Pathways>> Proteases>> Isocitrate Dehydrogenase (IDH)>>IDH889

IDH889

Catalog No.GC38640

IDH889 est un inhibiteur spécifique de l'isocitrate déshydrogénase 1 (IDH1) disponible par voie orale, pénétrant dans le cerveau, allostérique et mutant. IDH889 a une puissante sélectivité pour les mutations IDH1 R132 *, avec des IC50 de 0,02 μM, 0,072 μM et 1,38 μM pour IDH1R132H, IDH1R132C et IDH1wt, respectivement. IDH889 montre une puissante inhibition cellulaire de la production de R-2-hydroxyglutarate (2-HG) avec une IC50 de 0,014 μM.

Products are for research use only. Not for human use. We do not sell to patients.

IDH889 Chemical Structure

Cas No.: 1429179-07-6

Taille Prix Stock Qté
1mg
102,00 $US
En stock
5mg
306,00 $US
En stock
10mg
510,00 $US
En stock
25mg
867,00 $US
En stock
50mg
1 224,00 $US
En stock
100mg
1 835,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC50s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1R132H, IDH1R132C and IDH1wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC50 of 0.014 μM[1].

[1]. Levell JR, et al. Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. ACS Med Chem Lett. 2016 Dec 16;8(2):151-156.

Avis

Review for IDH889

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for IDH889

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.